VEENENDAAL, the Netherlands, September 3
- Despite Challenging Global Economic Conditions, Nucletron SurpassedProjections for the First Half Year
Nucletron, a global leader in radiation oncology, today announced strongfinancial results over the first half year of 2009. Despite challengingglobal economic conditions, Nucletron surpassed projections for the firsthalf year.
Net sales amounted to EUR 51.2 million, a 3% growth on like-for-likebasis compared to the first half of 2008. EBITDA in the first half of 2009amounted to EUR 6.3 million, a 53% increase compared to EUR 4.1 million overthe same period last year. As a result of the positive developments Nucletronexpects full year EBITDA to increase to EUR 19.0 million.
Jos Lamers, chief executive officer of Nucletron, comments: "Over thefirst six months of 2009, we have seen the results of our improved focus oninnovation and our increased marketing efforts. Our senior management team isat full strength after the appointment of three new team members with a bluechip background. Combining our strength in marketing and sales with theresearch & development capabilities of Isodose Control will make Nucletronone of the global leaders in brachytherapy. Given our many upcoming productreleases in the months ahead, we are on track to outperform our 2009 goals."
Among the several advancements made in the first half of 2009, Nucletronpartnered with Advanced Radiation Therapy (ART) to offer a revolutionarysolution for treating breast cancer. AccuBoost allows clinicians to useimage-guidance, as used in a standard mammography, to pinpoint radiationdirectly to the tumour site. This allows for much better accuracy intargeting the radiation to the cancerous area, while protecting the patients'healthy organs during treatment.
The business collaboration with Isodose Control is now in place. Thepartnership allows clinicians to benefit from Nucletron's leadership andstrength in brachytherapy with Isodose Control's track record of innovation.
Additionally, Nucletron launched its latest evolution in treatmentplanning for radiotherapy. Model-based segmentation in Oncentra MBS andvolumetric modulated arc therapy with Oncentra VMAT ensure quality, whiledramatically reducing the time needed to create treatment plans.
Visit our website http://www.nucletron.com
Nucletron is a global leader in Radiation Oncology, working with clinicalteams to realize innovative solutions that improve patient care. Nucletronstrives to offer the best possible choice of radiation modalities throughintegrated products, software and services. Critical to the Nucletronphilosophy is the establishment of close working relationships withindividual clinical teams - reconfiguring traditional boundaries betweencustomer and solution provider. Many Nucletron employees have clinicalexperience delivering oncology care, providing an in-depth understanding ofthe complex needs of clinicians.
SOURCE Nucletron B V